• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Evolving Approaches in HER2-Mutant NSCLC: Emerging Evidence and Practical Considerations

home / peer-exchange / evolving-approaches-in-her2-mutant-nsclc-emerging-evidence-and-practical-considerations

This AJMC Peer Exchange series examines the rapidly evolving HER2‑mutant NSCLC landscape, underscoring the need for comprehensive molecular testing and the potential of new targeted therapies. Panelists discuss critical challenges—including testing and access disparities, optimal therapeutic sequencing, and toxicity management—to guide clinical integration.

Value of Comprehensive Molecular Testing in NSCLC

EP. 1: Value of Comprehensive Molecular Testing in NSCLC

Ryan Haumschild, PharmD, MS, MBA, CPEL;Joshua K. Sabari, MD;Jingxiao Jin, MD;Fred Hirsch, MD, PhD
January 9th 2026

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.

Watch

Unmet Needs in HER2-Mutant NSCLC

EP. 2: Unmet Needs in HER2-Mutant NSCLC

Ryan Haumschild, PharmD, MS, MBA, CPEL;Joshua K. Sabari, MD;Jingxiao Jin, MD;Fred Hirsch, MD, PhD
January 9th 2026

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access.

Watch

© 2026 MJH Life Sciences
AJMC®
All rights reserved.